Teleflex, the Wayne, Pennsylvania-based medical technology company, has completed the sale of its OEM business to private equity firms Montagu and Kohlberg for $1.5 billion in cash, netting the company roughly $1.25 billion after taxes. It’s the largest single piece of a broader restructuring Teleflex has been executing over the past several months, one that’s reshaped what the company actually looks like going forward.
From a Planned Spin-Off to a Straight Sale
This deal didn’t come out of nowhere. Back in February 2025, Teleflex announced plans to split into two separate publicly traded companies, a “RemainCo” built around vascular access, interventional, and surgical businesses, and a “NewCo” that would house urology, acute care, and the OEM business. By December 2025, though, the company had changed course: rather than spinning NewCo off as its own public company, Teleflex agreed to sell those businesses outright. It struck deals to send acute care and interventional urology to Intersurgical for $530 million, and the OEM business,— the larger of the two , to Montagu and Kohlberg for $1.5 billion, together valued at $2.03 billion and roughly $1.8 billion in after-tax proceeds. The OEM sale has now closed; the Intersurgical deal is still expected to complete in the second half of 2026.Teleflex has described the OEM sale specifically as “a pivotal milestone” in that broader transformation, sharpening its focus down to what’s left: anesthesia, emergency medicine, interventional cardiology and radiology, surgical, and vascular access.
What Was Actually Sold
The OEM business Teleflex just parted with isn’t a small side operation. It’s a contract development and manufacturing business that’s spent more than 40 years supplying other medical device makers with custom-engineered components: interventional catheters, complex extrusions and micro-diameter tubing, film-insulated and coated wire, sheath and dilator introducers, and specialized sutures, largely serving fast-growing device categories like structural heart, neurovascular, electrophysiology, and urology. It runs seven facilities across the U.S., Ireland, and Mexico. Under its new ownership, the business has already rebranded as INGENYX, with Greg Stotts as CEO and Matt Jennings, a Senior Operating Partner at Kohlberg, as Executive Chairman. Stotts framed the new identity around the independence the sale provides: the company can now “invest further in the capabilities, expertise, and technologies” that support its customers directly, without being a division inside a larger public company’s broader strategy.
Where the Money Goes, and What’s Left at Teleflex
Teleflex says it’s putting the proceeds to fairly conventional use for a company mid-transformation: $800 million toward paying down debt, with the rest completing a $1 billion share repurchase authorization, both moves aimed at strengthening the balance sheet and returning capital to shareholders now that the divestiture program is largely done. What remains at Teleflex is a narrower but more focused portfolio built around brands like Arrow, LMA, QuikClot, Rüsch, Weck, and UroLift, concentrated in vascular access, interventional, and surgical care.
For a company headquartered just outside Philadelphia, this closes out a strategic reset that started as a planned corporate split and ended as a straightforward cash sale, netting Teleflex close to $1.8 billion combined while handing off businesses that, based on INGENYX’s early messaging, seem to be embracing life outside Teleflex’s umbrella just as readily.
